Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.
Аннотация
BACKGROUND
Although EGFR-TKIs have substantially improved outcomes in EGFR-mutated advanced NSCLC, acquired resistance ultimately leads to treatment failure in most patients. Yifeixiaoji Decoction (YFXJD), a traditional Chinese herbal formulation, has shown promise as an adjunctive strategy; however, evidence from prospective clinical studies for this specific formula remains limited. We therefore designed this trial to assess whether YFXJD could prolong progression-free survival when added to standard osimertinib therapy in advanced NSCLC.
METHODS
A total of 200 patients with stage IV EGFR-mutant NSCLC will be enrolled in a randomized, double-blind, placebo-controlled trial and allocated 1:1 to receive standard osimertinib therapy combined with either YFXJD granules or matched placebo. The primary endpoints is progression-free survival. Key secondary endpoints include change in TCM syndrome score, objective response rate, quality of life (EORTC QLQ-C30/LC13), safety (NCI CTCAE v5.0), and exploratory peripheral blood biomarker analyses.
EXPECTED
RESULTS
This trial will provide prospective evidence regarding the efficacy and safety of YFXJD as an adjunct to osimertinib therapy in patients with advanced EGFR-mutant NSCLC and will determine whether this approach influences clinical outcomes.
CLINICAL TRIAL REGISTRATION: https://itmctr.ccebtcm.org.cn, ITMCTR2025002306.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.